Scribe Therapeutics generated $1.918 million in collaboration Revenue for the three months ended June 30, 2026, down 61% from the comparable period, while reporting a $6.477 million net loss. For investors, the quarter combines lower partner activity with reduced Research and Development and general and administrative expenses.

Key Highlights

  • Scribe Therapeutics reported a net loss for the three months ended June 30, 2026.
  • Research and development expense declined from the comparable period.
  • Scribe Therapeutics said lower reimbursable research and development activity with Prevail reduced collaboration revenue.

Scribe Therapeutics, Inc. (NASDAQ: SCTX) generated $ 1,918,000 in collaboration revenue for the three months ended June 30, 2026, compared with $ 4,898,000 in the comparable period. The company reported a net loss for the three months ended June 30, 2026, compared with a net loss for the three months ended June 30, 2025. Lower reimbursable research and development activity with Prevail affected collaboration revenue.

Operating expenses totaled less than in the comparable period. Research and development expense was lower than in the comparable period, while general and administrative expense also declined. The loss from operations was lower than in the prior-year period. Interest income and other income, net, was lower, while interest expense also fell. The change in Fair Value of the convertible note produced income, compared with income in the comparable period. Net loss before income taxes was lower than in the comparable period, while the provision for income taxes was reported instead of a benefit.

Prevail Revenue Leads Collaboration Total

Prevail accounted for $ 1,918,000 of collaboration revenue in the quarter, compared with $ 4,778,000 in the comparable period. Sanofi generated no revenue, compared with $ 120,000 previously. Total collaboration revenue was therefore $ 1,918,000. The company attributed the Prevail decrease primarily to reduced reimbursable research and development activities, while Sanofi recorded no collaboration revenue in the current period. Research and development spending decreased across each listed category. Internal research expense, external research and development expense, and employee-related expense were all lower than in the comparable period. Facilities and overhead costs were lower than in the comparable period. Professional and consulting fees were also lower.

Six-Month Revenue Drops

For the six months ended June 30, 2026, collaboration revenue was $ 4,151,000, compared with $ 22,023,000 in the comparable period. Prevail contributed $ 4,151,000, compared with $ 21,568,000, while Sanofi contributed no revenue, compared with $ 455,000. The company said the six-month decrease reflected the absence of license revenue recognized in the prior-year period after a milestone was achieved, lower other collaboration revenue, and nonrecurring revenue recognition in 2025 tied to consideration allocated to a material substitution right. General and administrative expense was also lower, bringing total operating expenses below the comparable period. The six-month loss from operations was higher than in the comparable period.

Cash And Deferred Revenue

Cash, cash equivalents and marketable securities were reported as of June 30, 2026. Substantial doubt about its ability to continue as a Going Concern was alleviated by completion of its initial public offering and concurrent private placement. Deferred revenue stood at $ 39,173,000 at June 30, 2026, compared with $ 60,539,000 at June 30, 2025. The company recognized revenue of $ 1,850,000 from deferred revenue during the six months ended June 30, 2026. The registrant had 18,931,680 shares of common stock outstanding as of August 31, 2026. Deferred revenue related to the Prevail license agreement is expected to be recognized over the remaining term of the performance obligations.